{"id":10618,"date":"2026-02-12T12:27:09","date_gmt":"2026-02-12T12:27:09","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/10618\/"},"modified":"2026-02-12T12:27:09","modified_gmt":"2026-02-12T12:27:09","slug":"novo-nordisk-set-to-make-wegovy-pill-in-ireland-for-markets-outside-us-the-irish-times","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/10618\/","title":{"rendered":"Novo Nordisk set to make Wegovy pill in Ireland for markets outside US \u2013 The Irish Times"},"content":{"rendered":"<p class=\"c-paragraph paywall \">Wight loss drug company <a href=\"https:\/\/www.irishtimes.com\/tags\/novo-nordisk\/\" target=\"_self\" rel=\"nofollow noopener\" title=\"https:\/\/www.irishtimes.com\/tags\/novo-nordisk\/\">Novo Nordisk<\/a> will expand its facility in Athlone, chief executive Mike Doustdar says.<\/p>\n<p class=\"c-paragraph paywall \">The launch of the <a href=\"https:\/\/www.irishtimes.com\/tags\/wegovy\/\" target=\"_self\" rel=\"nofollow noopener\" title=\"https:\/\/www.irishtimes.com\/tags\/wegovy\/\">Wegovy <\/a>in pill form in early January has been one of the most successful pharmaceutical debuts ever, with more than 240,000 Americans taking it already, Doustdar said.<\/p>\n<p class=\"c-paragraph paywall \">Novo is hoping the pill will form a big part of its fight to reclaim share in a weight-loss market it once dominated and make up ground lost to rival <a href=\"https:\/\/www.irishtimes.com\/tags\/eli-lilly\/\" target=\"_self\" rel=\"nofollow noopener\" title=\"https:\/\/www.irishtimes.com\/tags\/eli-lilly\/\">Eli Lilly<\/a>, which makes the blockbuster drug <a href=\"https:\/\/www.irishtimes.com\/tags\/zepbound\/\" target=\"_self\" rel=\"nofollow noopener\" title=\"https:\/\/www.irishtimes.com\/tags\/zepbound\/\">Zepbound<\/a>.<\/p>\n<p class=\"c-paragraph paywall \">The Athlone investment will see the company manufacture the pill form of their weight loss drug in Ireland for markets outside the United States. <\/p>\n<p class=\"c-paragraph paywall \">\u201cIf we were about to throw in the towel, we would not be investing in factories in Ireland,\u201d Doustdar said.<\/p>\n<p class=\"c-paragraph paywall \">Around two years ago, the Danish drugmaker pulled out of plans to build a factory near Dublin and it cut jobs at the Athlone site in September last year, according to media reports.<\/p>\n<p class=\"c-paragraph paywall \">Doustdar declined to comment on the scale of the investment.<\/p>\n<p class=\"c-paragraph paywall \">Ireland is an international hub for pharmaceutical manufacturing. Lilly produces active ingredients for its blockbuster weight-loss and diabetes drugs there. <\/p>\n<p class=\"c-paragraph paywall \">The State\u2019s economy is highly dependent on US investment and it has found itself at the centre of President Donald Trump\u2019s threats to reshore profits and impose tariffs.<\/p>\n<p class=\"c-paragraph paywall \">Novo disappointed investors by forecasting a bigger-than-expected drop in sales this year, evidence of an intensifying price war in obesity drugs. Novo makes the obesity pill for the US market in the US. \u2013 Bloomberg<\/p>\n","protected":false},"excerpt":{"rendered":"Wight loss drug company Novo Nordisk will expand its facility in Athlone, chief executive Mike Doustdar says. The&hellip;\n","protected":false},"author":2,"featured_media":10619,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[276,272,1910,3103],"class_list":{"0":"post-10618","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-eli-lilly","9":"tag-novo-nordisk","10":"tag-wegovy","11":"tag-zepbound"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/10618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=10618"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/10618\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/10619"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=10618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=10618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=10618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}